The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Integrative Clinical Genomics of Advanced Prostate Cancer
Open accessAbstract
Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. We identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF. Moreover, aberrations of BRCA2, BRCA1, and ATM were observed at substantially higher frequencies (19.3% overall) compared to those in primary prostate cancers. 89% of affected individuals harbored a clinically actionable aberration, including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. This cohort study provides clinically actionable information that could impact treatment decisions for these affected individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The androgen receptor (AR) is a critical driver of prostate cancer (PCa).”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“The consortium utilized two sequencing and analysis centers, one centralized digital pathology review center, and one centralized data visualization portal (Cerami et al., 2012; Gao et al., 2013; Robinson et al., 2011; Thorvaldsdóttir et al., 2013).”
Self-citationRobinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · cited 3×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationTrapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · cited 1×
“…analysis reveals that the majority of affected individuals with metastatic castration-resistant prostate cancer harbor clinically actionable molecular alterations, highlighting the need for genetic counseling to inform precision medicine in affected individuals with advanced prostate cancer.”
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965 · cited 2×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Self-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · cited 1×
“…on the PI3K pathway, PIK3CB-specific inhibitors may have utility in affected individuals with mutation, amplification, and/or fusion of this gene (Schwartz et al., 2015); multiple affected individuals who achieved durable (>1 year) responses to PIK3CB-specificin inhibition harbored activating…”
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Self-citationRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · cited 1×
“Among chimeric fusion transcripts identified, recurrent ETS fusions (Tomlins et al., 2005) were observed in 84 cases (56%), of which the majority were fused to ERG and others to FLI1, ETV4, and ETV5 (Figure 3B).”
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,007
Unal, B., Kuzu, O. F., Jin, Y., Osorio, D., Kildal, W., Pradhan, M., Kung, S. H. Y., Oo, H. Z., Daugaard, M., Vendelbo, M. H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53039-1 · Cited by 53
“To model advanced PCa, which commonly involves MYC ampli fi cation and PTEN loss in patient tumors 23 – 25 , we generated a PTEN KO Myc-CaP cell line by CRISPR-Cas9 genome editing.”
Redirecting the pioneering function of FOXA1 with covalent small molecules
Won, S. J., Zhang, Y., Reinhardt, C. J., Hargis, L. M., MacRae, N. S., DeMeester, K. E., Njomen, E., Remsberg, J. R., Melillo, B. N., Cravatt, B. F., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.09.024 · Cited by 43
Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4
Sowalsky, A. G., Kissick, H. T., Gerrin, S. J., Schaefer, R. J., Xia, Z., Russo, J. W., Arredouani, M. S., Bubley, G. J., Sanda, M. G., Li, W., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2414 · Cited by 44
Self-citationThe nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein
Chen, M., Nowak, D. G., Narula, N., Robinson, B. D., Watrud, K. E., Ambrico, A. J., Herzka, T. M., Zeeman, M. E., Minderer, M., Zheng, W., et al. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201604025 · Cited by 45
Self-citationMutations in BRCA2 and taxane resistance in prostate cancer
Nientiedt, C., Heller, M., Endris, V., Volckmar, A., Zschäbitz, S., Tapia-Laliena, M. Á., Duensing, A. U., Jäger, D., Schirmacher, P., Sültmann, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04897-x · Cited by 43
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers
Rescigno, P., Lorente, D., Dolling, D. I., Ferraldeschi, R., Rodrigues, D. N., Riisnaes, R., Miranda, S., Bianchini, D., Zafeiriou, Z., Sideris, S., et al. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.02.006 · Cited by 44
Self-citationTherapeutic potential of ReACp53 targeting mutant p53 protein in CRPC
Zhang, Y., Xu, L., Chang, Y., Li, Y., Butler, W., Jin, E., Wang, A., Tao, Y., Chen, X., Liang, C. Y., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0172-z · Cited by 44
Lu, C., Terbuch, A., Dolling, D. I., Yu, J., Wang, H., Chen, Y., Fountain, J., Bertan, C. M., Sharp, A., Carreira, S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.473 · Cited by 44
Self-citationEffects of Medical Treatment of Prostate Cancer on Bone Health
Formenti, A. M., Volta, A. D., di Filippo, L., Berruti, A., & Giustina, A. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.12.004 · Cited by 45
Erickson, A. M., Hayes, A., Rajakumar, T., Verrill, C. L., Bryant, R. J., Hamdy, F. C., Wedge, D. C., Woodcock, D. J., Mills, I. G., & Lamb, A. D. G. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.02.008 · Cited by 45
Privé, B. M., Slootbeek, P. H. J., Laarhuis, B. I., Naga, S. P., van der Doelen, M. J., van Kalmthout, L. W. M., de Keizer, B., Ezziddin, S., Kratochwil, C., Morgenstern, A., et al. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00424-2 · Cited by 44
Reardon, B. M., Moore, N. D., Moore, N., Kofman, E. R., AlDubayan, S. H., Cheung, A. T. M., Conway, J. R., Elmarakeby, H., Imamović, A., Kamran, S. C., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00243-3 · Cited by 43
Rao, A., Moka, N., Hamstra, D. A., & Ryan, C. J. (2022) · Cancers · doi:10.3390/cancers14030801 · Cited by 44
YAP antagonizes TEAD‐mediated AR signaling and prostate cancer growth
Zhuo, S., Li, X., Cho, Y. S., Liu, Y., Yang, Y., Zhu, J., & Jiang, J. (2023) · The EMBO Journal · doi:10.15252/embj.2022112184 · Cited by 44
Germain, L., Lafront, C., Paquette, V., Neveu, B., Paquette, J., Pouliot, F., & Audet‐Walsh, É. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00726-1 · Cited by 47
Qian, C., Yang, Q., Rotinen, M., Huang, R., Kim, H., Gallent, B., Yan, Y., Cadaneanu, R. M., Zhang, B., Kaochar, S., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae547 · Cited by 49
Self-citationTien, J. C.-Y., Luo, J., Chang, Y., Zhang, Y., Cheng, Y., Wang, X., Yang, J., Mannan, R., Mahapatra, S., Shah, P., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101758 · Cited by 45
Self-citationChattopadhyay, I., Wang, J., Qin, M., Gao, L., Holtz, R., Vessella, R. L., Leach, R. W., & Gelman, I. H. (2016) · Oncotarget · doi:10.18632/oncotarget.14401 · Cited by 43
Transcriptomic and genomic features of invasive lobular breast cancer
Desmedt, C., Zoppoli, G. M., Sotiriou, C. P., & Salgado, R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.007 · Cited by 43
Shen, M., Chen, J., Luo, C., Lee, S., Li, C., Yang, Y., Tsai, Y.-H. J., Ho, B.-C., Bao, L., Lee, T., et al. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700701 · Cited by 43
Self-citationCamacho, N., Loo, P. V., Edwards, S. E., Kay, J. D., Matthews, L. H., Haase, K., Clark, J., Dennis, N. M., Thomas, S. A., Kremeyer, B., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1007001 · Cited by 43
Gillard, M., Lack, J., Pontier, A. L., Gandla, D., Hatcher, D. M., Sowalsky, A. G., Rodriguez-Nieves, J. A., Griend, D. J. V., Paner, G. P., & VanderWeele, D. J. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.12.003 · Cited by 43
Mohammad, O. S., Nyquist, M. D., Schweizer, M. T., Balk, S. P., Corey, E., Plymate, S. R., Nelson, P. S., & Mostaghel, E. A. (2017) · Cancers · doi:10.3390/cancers9120166 · Cited by 42
Self-citationJaiswal, P. K., Koul, S., Shanmugam, P. S. T., & Koul, H. K. (2018) · Scientific Reports · doi:10.1038/s41598-018-25798-7 · Cited by 43
Role of RNF20 in cancer development and progression – a comprehensive review
Sethi, G., Shanmugam, M. K., Arfuso, F., & Kumar, A. P. (2018) · Bioscience Reports · doi:10.1042/bsr20171287 · Cited by 44
Frank, S. B., Nelson, P. S., & Vasioukhin, V. I. (2018) · F1000Research · doi:10.12688/f1000research.14499.1 · Cited by 45
Self-citationMolecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer
Mollica, V., Nunno, V. D., Cimadamore, A., Antonio Lopez-beltran, B., Liang Cheng, C., Santoni, M., Scarpelli, M., Montironi, R., & Massari, F. (2019) · Cells · doi:10.3390/cells8010043 · Cited by 43
Kaur, H. B., Lu, J., Guedes, L. B., Maldonado, L., Reitz, L., Barber, J. R., Marzo, A. M. D., Tomlins, S. A., Sfanos, K. S., Eisenberger, M. A., et al. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.02.006 · Cited by 43
Self-citationZhang, L., Song, Y., Ling, Z., Li, Y., Ren, X., Yang, J., Wang, Z., Xia, J., Zhang, W., & Cheng, B. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.076 · Cited by 43
RetractedCao, S., Ma, T., Ungerleider, N., Roberts, C., Kobelski, M. M., Jin, L., Concha, M., Wang, X., Baddoo, M., Nguyen, H. M., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0947-7 · Cited by 43
Intratumoral heterogeneity and genetic characteristics of prostate cancer
Wu, B., Lu, X. L., Shen, H., Yuan, X., Wang, X., Yin, N., Sun, L., Shen, P., Hu, C., Jiang, H., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32961 · Cited by 43
Tang, S., Sethunath, V., Metaferia, N. Y., Nogueira, M. F., Gallant, D. S., Garner, E. R., Lairson, L. A., Penney, C. M., Li, J., Gelbard, M. K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110417 · Cited by 42
TP53 alterations of hormone-naïve prostate cancer in the Chinese population
Liu, Z., Guo, H., Zhu, Y., Xia, Y., Cui, J., Shi, K., Fan, Y., Shi, B., & Chen, S. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-00302-3 · Cited by 41
Coleman, I. M., Sarkar, N. D., Morrissey, C. M., Xin, L., Roudier, M. P., Sayar, E., Li, D., Corey, E., Haffner, M. C., & Nelson, P. S. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4289 · Cited by 46
Self-citationValsecchi, A. A., Dionisio, R., Panepinto, O., Paparo, J., Palicelli, A., Vignani, F., & Maïo, M. D. (2023) · Cancers · doi:10.3390/cancers15092435 · Cited by 43
“Fixed Random Gallagher, 2012 88 3.409 0.709 to 9.641 2.24 8.49 Robinson, 2015 150 0.667 0.0169 to 3.658 3.80 9.81 Mateo, 2015 49 0.000 0.000 to 7.252 1.26 6.77 Pritchard, 2016 692 0.867 0.319 to 1.878 17.44 11.87 Antonarakis, 2018 172 0.581 0.0147 to 3.197 4.35 10.09 Carneiro, 2018 1534 0.000 0.000…”
InfluentialLactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications?
Chetta, P., Sriram, R., & Zadra, G. (2023) · Cancers · doi:10.3390/cancers15133473 · Cited by 45
The molecular underpinnings of prostate cancer: impacts on management and pathology practice
Rodrigues, D. N., Boysen, G., Sumanasuriya, S., Seed, G., Marzo, A. M. D., & Bono, J. S. D. (2016) · The Journal of Pathology · doi:10.1002/path.4826 · Cited by 41
Clinical Use of Precision Oncology Decision Support
Johnson, A. M., Khotskaya, Y. B., Brusco, L., Zeng, J., Holla, V. R., Bailey, A. M., Litzenburger, B. C., Sánchez, N., Shufean, M. A., Piha-Paul, S. A., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00036 · Cited by 42
Ko, H., Berk, M. P., Chung, Y.-M., Willard, B. B., Bareja, R., Rubin, M. A., Sboner, A., & Sharifi, N. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.081 · Cited by 42
Self-citationSharma, N. V., Pellegrini, K. L., Ouellet, V., Giuste, F., Ramalingam, S. S., Watanabe, K. A., Adam-Granger, É., Fossouo, L., You, S., Freeman, M. R., et al. (2018) · Cancers · doi:10.3390/cancers10100379 · Cited by 41
Hirotsu, Y., Yokoyama, H., Amemiya, K., Hagimoto, T., Daimon, H., Hosaka, K., Oyama, T., Mochizuki, H., & Omata, M. (2019) · Cancer Science · doi:10.1111/cas.14155 · Cited by 43
Simmons, A. D., Nguyen, M., & Pintus, E. (2020) · BMC Cancer · doi:10.1186/s12885-020-6657-2 · Cited by 41
Genomic and Clinicopathologic Characterization of ATM -deficient Prostate Cancer
Kaur, H. B., Salles, D. C., Murali, S., Hicks, J. L., Nguyen, M., Pritchard, C. C., Marzo, A. M. D., Lanchbury, J. S. S., Trock, B. J., Isaacs, W. B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0764 · Cited by 46
Self-citationKwan, E. M., Dai, C., Fettke, H., Hauser, C., Docanto, M. M., Bukczynska, P. E., Ng, N., Foroughi, S., Graham, L.-J. K., Mahon, K. L., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00424 · Cited by 44
Molecular pathology of prostate cancer: a practical approach
Vlajnic, T., & Bubendorf, L. (2020) · Pathology · doi:10.1016/j.pathol.2020.10.003 · Cited by 41
Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer
Lorenzin, F., & Demichelis, F. (2022) · Cancers · doi:10.3390/cancers14051118 · Cited by 42
Self-citationFranzese, O., & Graziani, G. (2022) · Cancers · doi:10.3390/cancers14225633 · Cited by 44
Prostate organoids: emerging experimental tools for translational research
Beshiri, M. L., Agarwal, S., Yin, J. J., & Kelly, K. (2023) · Journal of Clinical Investigation · doi:10.1172/jci169616 · Cited by 40
“Insight into the genetic determinants of prostate cancer has come from multi-institutional coordinated efforts to sequence large sets of patient tissue samples, and CRPC has proven to be highly genetically diverse (6–8).”
BackgroundThe contemporary management of prostate cancer
Chakrabarti, D., Albertsen, P. C., Adkins, A., Kishan, A. U., Murthy, V., Parker, C. C., Pathmanathan, A. U., Reid, A. H. M., Sartor, O., van As, N. J., et al. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70020 · Cited by 50
Fizazi, K. S., Azad, A., Matsubara, N., Carles, J., Fay, A. P., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Voog, É., Jones, R. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00683-x · Cited by 46
Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases
Varenhorst, E., Klaff, R., Berglund, A., Hedlund, P. O., Sandblom, G., & the Scandinavian Prostate Cancer Group (SPCG) Trial No. 5 (2016) · Cancer Medicine · doi:10.1002/cam4.594 · Cited by 41
DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities
Dhawan, M., Ryan, C. J., & Ashworth, A. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0135 · Cited by 41
Exploiting Epigenetic Alterations in Prostate Cancer
Baumgart, S. J., & Haendler, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051017 · Cited by 44
Herroon, M. K., Rajagurubandara, E. N., Diedrich, J. D., Heath, E. I., & Podgorski, I. (2018) · Scientific Reports · doi:10.1038/s41598-017-17800-5 · Cited by 42
Self-citationKohli, M., Li, J., Du, M., Hillman, D. W., Dehm, S. M., Tan, W. W., Carlson, R. E., Campion, M. B., Wang, L., Wang, L., et al. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0043-z · Cited by 43
DNA repair defects in prostate cancer: impact for screening, prognostication and treatment
Warner, E. W., Yip, S., Chi, K. N., & Wyatt, A. W. (2018) · British Journal of Urology · doi:10.1111/bju.14576 · Cited by 42
BRCA1 and homologous recombination: implications from mouse embryonic development
Liu, Y., & Lu, L. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00412-4 · Cited by 44
Microstructure-based techniques for single-cell manipulation and analysis
Pang, L., Ding, J., Liu, X.-X., Yuan, H., Ge, Y., Fan, J., & Fan, S. (2020) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2020.115940 · Cited by 40
Clinical Applications of Molecular Biomarkers in Prostate Cancer
Couñago, F., López‐Campos, F., Díaz-Gavela, A. A., Almagro, E., Fernández‐Pascual, E., Henriquez, I., Lozano, R., Linares, E., Iturriaga, A. G., de Velasco, G., et al. (2020) · Cancers · doi:10.3390/cancers12061550 · Cited by 42
Computational methods-guided design of modulators targeting protein-protein interactions (PPIs)
Qiu, Y., Li, X., He, X., Pu, J., Zhang, J., & Lu, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112764 · Cited by 42
Merseburger, A. S., Waldron, N. R., Ribal, M. J., Heidenreich, A., Perner, S., Fizazi, K. S., Sternberg, C. N., Mateo, J., Wirth, M. P., Castro, E., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.12.039 · Cited by 41
Self-citationAndrogen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer
Scaravilli, M., Koivukoski, S., & Latonen, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.623809 · Cited by 42
Kukkonen, K., Taavitsainen, S., Huhtala, L., Uusi-Mäkelä, J., Granberg, K. J., Nykter, M., & Urbanucci, A. (2021) · Cancers · doi:10.3390/cancers13133325 · Cited by 47
RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition
Han, W., Liu, M., Han, D. G., Li, M., Toure, A. A., Wang, Z., Besschetnova, A., Patalano, S. C., Macoska, J. A., Gao, S., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02135-3 · Cited by 41
Thiery-Vuillemin, A., Bono, J. S. D., Hussain, M., Roubaud, G., Procopio, G., Shore, N., Fizazi, K. S., dos Anjos, G. M., Gravis, G., Joung, J. Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00017-1 · Cited by 41
Self-citationEmerging Biomarker-Guided Therapies in Prostate Cancer
Deluce, J. E., Cardenas, L. M., Lalani, A. A., Vareki, S. M., & Fernandes, R. (2022) · Current Oncology · doi:10.3390/curroncol29070400 · Cited by 46
Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer
Chakraborty, G., Gupta, K. R., & Kyprianou, N. (2023) · Nature Communications · doi:10.1038/s41467-023-36253-1 · Cited by 41
Impact of DNA damage repair alterations on prostate cancer progression and metastasis
Lukashchuk, N., Barnicle, A., Adelman, C. A., Armenia, J., Kang, J., Barrett, J. C., & Harrington, E. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1162644 · Cited by 43
Maekawa, S., Takata, R., & Obara, W. (2024) · Cancers · doi:10.3390/cancers16030523 · Cited by 49
“SPOP mutations, while present, are relatively less frequent in metastatic samples [10,36,51,52].”
BackgroundInfluentialUnveiling novel double-negative prostate cancer subtypes through single-cell RNA sequencing analysis
Cheng, S., Li, L., Yeh, Y. A., Shi, Y., Franco, O. E., Corey, E., & Yu, X. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00667-x · Cited by 41
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis
Parolia, A., Eyunni, S., Verma, B. K., Young, E., Liu, Y., Liu, L., George, J. M., Aras, S., Das, C. K., Mannan, R., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01893-6 · Cited by 40
Self-citationCastration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
Lorente, D., Omlin, A. G., Zafeiriou, Z., Rodrigues, D. N., Pérez-López, R., Pezaro, C., Mehra, N., Sheridan, E., Figueiredo, I., Riisnaes, R., et al. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.04.016 · Cited by 40
Self-citationClinical value of R-spondins in triple-negative and metaplastic breast cancers
Coussy, F., Lallemand, F., Vacher, S., Schnitzler, A., Chemlali, W., Caly, M., Nicolas, A., Richon, S., Meseure, D., Botty, R. E., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.131 · Cited by 42
Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human Tumors
Cusan, M., Mungo, G., Zompit, M. D. M., Segatto, I., Belletti, B., & Baldassarre, G. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00393 · Cited by 42
Yadav, S., Kowolik, C. M., Lin, M., Zuro, D. M., Hui, S. K., Riggs, A. D., & Horne, D. A. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22913 · Cited by 39
Faugeroux, V., Lefèbvre, C., Pailler, E., Pierron, V., Marcaillou, C., Tourlet, S., Billiot, F., Doğan, S., Oulhen, M., Vielh, P. R., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2018.12.005 · Cited by 41
Systemic treatment for metastatic prostate cancer
Gravis, G. (2019) · Asian journal of urology · doi:10.1016/j.ajur.2019.02.002 · Cited by 43
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
Mazzu, Y. Z., Armenia, J., Nandakumar, S., Chakraborty, G., Yoshikawa, Y., Jehane, L. E., Lee, G. M., Atiq, M. O., Khan, N. A., Schultz, N. D., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12706 · Cited by 40
Self-citationDong, B., Fan, L., Yang, B., Chen, W., Li, Y., Wu, K., Zhang, F., Dong, H., Cheng, H., Pan, J., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7663 · Cited by 42
Self-citationMa, F., Arai, S., Wang, K., Calagua, C., Yuan, A. R., Poluben, L., Gu, Z., Russo, J. W., Einstein, D. J., Ye, H., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1807 · Cited by 40
Self-citationDistinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors
Savill, K. M. Z., Lee, B. B., Oeh, J., Lin, J. M., Lin, E., Chung, W., Young, A. E., Chen, W., Miś, M., Mesh, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29655-0 · Cited by 40
Regulation and role of CAMKK2 in prostate cancer
Pulliam, T. L., Goli, P., Awad, D., Lin, C., Wilkenfeld, S. R., & Frigo, D. E. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00588-z · Cited by 36
Health inequity drives disease biology to create disparities in prostate cancer outcomes
Nelson, W. G., Brawley, O. W., Isaacs, W. B., Platz, E. A., Yegnasubramanian, S., Sfanos, K. S., Lotan, T. L., & Marzo, A. M. D. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155031 · Cited by 42
Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta‐analysis
Chen, J., Shi, M., Choi, S. Y. C., Wang, Y., Lin, D., Zeng, H., & Wang, Y. Z. (2023) · BJUI Compass · doi:10.1002/bco2.212 · Cited by 39
“This is a similar mutation profile to advanced prostate adenocarcinoma.(30,31) Taken together, these findings strongly suggest that genomic testing should be performed in NEPC patients to help decide appropriate treatments.”
ResultInfluentialLuo, J. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.178490 · Cited by 41
Therapy assessment in prostate cancer using choline and PSMA PET/CT
Ceci, F., Herrmann, K., Hadaschik, B. A., Castellucci, P., & Fanti, S. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3723-3 · Cited by 38
A regulatory circuit HP1γ/miR-451a/c-Myc promotes prostate cancer progression
Chang, C., Liu, J., He, W., Qu, M., Huang, X., Deng, Y., Shen, L., Zhao, X., Guo, H., Jiang, J., et al. (2017) · Oncogene · doi:10.1038/onc.2017.332 · Cited by 39
Indel detection from DNA and RNA sequencing data with transIndel
Yang, R., Etten, J. L. V., & Dehm, S. M. (2018) · BMC Genomics · doi:10.1186/s12864-018-4671-4 · Cited by 39
Parry, M., Srivastava, S., Ali, A., Cannistraci, A., Antonello, J., Barros-Silva, J. D., Ubertini, V., Ramani, V., Lau, M., Shanks, J. H., et al. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.08.005 · Cited by 39
Zhu, Z., Chung, Y., Sergeeva, O., Kepe, V., Berk, M. P., Li, J., Ko, H., Li, Z., Petro, M., DiFilippo, F. P., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004846 · Cited by 40
Olcina, M. M., Balanis, N. G., Kim, R. K., Aksoy, B. A., Kodysh, J., Thompson, M. J., Hammerbacher, J., Graeber, T. G., & Giaccia, A. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.093 · Cited by 39
SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer
Li, H., Wang, L., Li, Z., Xu, G., Li, M., Tang, Q., Wu, C., & Lu, Z. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0343-5 · Cited by 39
Miyahira, A. K., Sharp, A., Ellis, L., Jones, J. C., Kaochar, S., Larman, H. B., Quigley, D. A., Ye, H., Simons, J. W., Pienta, K. J., et al. (2019) · The Prostate · doi:10.1002/pros.23934 · Cited by 40
Self-citationKokal, M., Mirzakhani, K., Pungsrinont, T., & Baniahmad, A. (2020) · Cancers · doi:10.3390/cancers12071833 · Cited by 39
Saunders, E. J., Kote‐Jarai, Z., & Eeles, R. A. (2021) · Cancers · doi:10.3390/cancers13040760 · Cited by 38
Melo, C. M., Vidotto, T., Chaves, L. P., Lautert-Dutra, W., dos Reis, R. B., & Squire, J. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179550 · Cited by 42
P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer
Maynard, J. P., Lu, J., Vidal, I., Hicks, J. L., Mummert, L. A., Ali, T., Kempski, R., Carter, A. M., Sosa, R. Y., Peiffer, L. B., et al. (2021) · The Journal of Pathology · doi:10.1002/path.5815 · Cited by 39
Hung, C.-L., Liu, H.-H., Fu, C., Yeh, H.-H., Hu, T.-L., Kuo, Z., Lin, Y.-C., Jhang, M.-R., Hwang, C.-S., Hsu, H., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104500 · Cited by 40
“26,27 Those such as AR-V3 and AR-V9 are further demonstrated to co-express with AR-V7 in metastatic CRPC tumors predictive to be abiraterone resistance.”
Spans, L., den Broeck, T. V., Smeets, E., Preković, S., Thienpont, B., Lambrechts, D., Karnes, R. J., Erho, N., Alshalalfa, M., Davicioni, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8220 · Cited by 39
Das, R., Sjöström, M., Shrestha, R., Yogodzinski, C., Egusa, E. A., Chesner, L. N., Chen, W. S., Chou, J., Dang, D. K., Swinderman, J. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24919-7 · Cited by 38
Self-citation
Metadata
- Authors
- Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., Beltran, H., Abida, W., Bradley, R. K., Vinson, J., Cao, X., Vats, P., Kunju, L. P., Hussain, M., Feng, F. Y., Tomlins, S. A., Cooney, K. A., Smith, D. C., Brennan, C., Siddiqui, J., Mehra, R., Chen, Y., Rathkopf, D. E., Morris, M. J., Solomon, S. B., Durack, J. C., Reuter, V. E., Gopalan, A., Gao, J., Loda, M., Lis, R. T., Bowden, M., Balk, S. P., Gaviola, G., Sougnez, C., Gupta, M., Yu, E. Y., Mostaghel, E. A., Cheng, H. H., Mulcahy, H., True, L. D., Plymate, S. R., Dvinge, H., Ferraldeschi, R., Flohr, P., Miranda, S., Zafeiriou, Z., Tunariu, N., Mateo, J., Perez-Lopez, R., Demichelis, F., Robinson, B. D., Schiffman, M., Nanus, D. M., Tagawa, S. T., Sigaras, A., Eng, K. W., Elemento, O., Sboner, A., Heath, E. I., Scher, H. I., Pienta, K. J., Kantoff, P., de Bono, J. S., Rubin, M. A., Nelson, P. S., Garraway, L. A., Sawyers, C. L., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Memorial Sloan Kettering Cancer Center (US)
- NewYork–Presbyterian Hospital (US)
- University of Washington (US)
- Dana-Farber Cancer Institute (US)
- Royal Marsden NHS Foundation Trust (GB)
- Howard Hughes Medical Institute (US)
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- University of Washington Medical Center (US)
- University of Trento (IT)
- Cornell University (US)
- Wayne State University (US)
- Johns Hopkins University (US)
- Corresponding author
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- ORCID
- Robinson, Dan
- Schultz, Nikolaus
- Mosquera, Juan-Miguel
- Montgomery, Bruce
- Taplin, Mary-Ellen
- Pritchard, Colin C.
- Attard, Gerhardt
- Beltran, Himisha
- Abida, Wassim
- Bradley, Robert K.
- Vinson, Jake
- Cao, Xuhong
- Vats, Pankaj
- Kunju, Lakshmi P.
- Hussain, Maha
- Feng, Felix Y.
- Tomlins, Scott A.
- Cooney, Kathleen A.
- Smith, David C.
- Brennan, Christine
- Siddiqui, Javed
- Mehra, Rohit
- Chen, Yu
- Rathkopf, Dana E.
- Morris, Michael J.
- Solomon, Stephen B.
- Durack, Jeremy C.
- Gopalan, Anuradha
- Gao, Jianjiong
- Loda, Massimo
- Lis, Rosina T.
- Bowden, Michaela
- Gupta, Manaswi
- Yu, Evan Y.
- Mostaghel, Elahe A.
- Cheng, Heather H.
- Mulcahy, Hyojeong
- True, Lawrence D.
- Plymate, Stephen R.
- Dvinge, Heidi
- Flohr, Penny
- Miranda, Susana
- Zafeiriou, Zafeiris
- Tunariu, Nina
- Demichelis, Francesca
- Robinson, Brian D.
- Schiffman, Marc
- Nanus, David M.
- Tagawa, Scott T.
- Sigaras, Alexandros
- Eng, Kenneth W.
- Elemento, Olivier
- Sboner, Andrea
- Heath, Elisabeth I.
- Scher, Howard I.
- Pienta, Kenneth J.
- Kantoff, Philip
- Rubin, Mark A.
- Nelson, Peter S.
- Garraway, Levi A.
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 161
- Issue
- 5
- Pages
- 1215-1228
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4484602
- OpenAlex
- W1578291413
- Cited by
- 3,645
- References
- 64
- Citations by year
- 2026: 178 · 2025: 258 · 2024: 320 · 2023: 363 · 2022: 360 · 2021: 392 · 2020: 378 · 2019: 346 · 2018: 358 · 2017: 355 · 2016: 263 · 2015: 63
- FWCI
- 273.95
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-07-16)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Iris (University of Trento) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Cancer Research UK (13239)
- National Institute for Health and Care Research (CL-2008-22-001)
- Prostate Cancer UK (CEO13_2-002, PG12-49)
- National Institutes of Health (DP2OD002750)
- Medical Research Council (MR/M003272/1)
- National Human Genome Research Institute (UM1HG006508)
- National Cancer Institute (P50 CA 90381, R01CA136578, L30 CA111031, K08CA188615, R21CA128352, U01CA111275, P50CA090381, R01CA131945, UO1CA111275, L30 CA103810, R01CA116337, R01CA129435, P50CA069568, K08CA115927, R01CA092629, R01CA155169, R01CA193910, R01CA085912, P30CA008748, P01CA163227, P50CA097186, P50CA186786, P50CA092629, P30CA006516, R01CA193837)
- National Institute of General Medical Sciences (T32GM007266, R01GM107427)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- metastatic castration-resistant prostate cancer, exome sequencing, transcriptome sequencing, actionable genomic alterations, androgen receptor alterations, ETS gene fusions, TP53, PTEN, R-spondin, APC, β-catenin, BRCA2, BRCA1, ATM, germline pathogenic variants, precision medicine
- MeSH terms
- Humans, Male, Mutation, Neoplasm Metastasis, Cohort Studies, Gene Expression Profiling, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
